about
The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons. Implication in a pathological mechanism related to Alzheimer diseaseFunctional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology.Synphilin-1 enhances α-synuclein aggregation in yeast and contributes to cellular stress and cell death in a Sir2-dependent mannerA major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditionsTau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnosticsAdenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics.Ectosomes: a new mechanism for non-exosomal secretion of tau protein.Amyloid Precursor Protein (APP) Metabolites APP Intracellular Fragment (AICD), Aβ42, and Tau in Nuclear Roles.Loss of Tau protein affects the structure, transcription and repair of neuronal pericentromeric heterochromatinAggresome formation and segregation of inclusions influence toxicity of α-synuclein and synphilin-1 in yeast.Nuclear magnetic resonance spectroscopy characterization of interaction of Tau with DNA and its regulation by phosphorylation.Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo.Pin1 allows for differential Tau dephosphorylation in neuronal cells.Chronically stressed or stress-preconditioned neurons fail to maintain stress granule assembly.Cognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion.Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease.The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity.A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists.Chronic intoxication with 3-nitropropionic acid in rats induces the loss of striatal dopamine terminals without affecting nigral cell viability.Increased Alix (apoptosis-linked gene-2 interacting protein X) immunoreactivity in the degenerating striatum of rats chronically treated by 3-nitropropionic acid.Minocycline in phenotypic models of Huntington's disease.Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain.Atypical, non-standard functions of the microtubule associated Tau protein.Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration.Altered neuronal excitability in cerebellar granule cells of mice lacking calretinin.Anorexigenic lipopeptides ameliorate central insulin signaling and attenuate tau phosphorylation in hippocampi of mice with monosodium glutamate-induced obesity.In Vivo Hyperthermic Stress Model: An Easy Tool to Study the Effects of Oxidative Stress on Neuronal Tau Functionality in Mouse Brain.Pharmacological characterization of new cholecystokinin analogues.Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology.Novel Lipidized Analog of Prolactin-Releasing Peptide Improves Memory Impairment and Attenuates Hyperphosphorylation of Tau Protein in a Mouse Model of Tauopathy.[Molecular actors in Alzheimer's disease: which diagnostic and therapeutic consequences?].Tau/DDX6 interaction increases microRNA activitySynthesis and biological evaluation of cholecystokinin analogs in which the Asp-Phe-NH2 moiety has been replaced by a 3-amino-7-phenylheptanoic acid or a 3-amino-6-(phenyloxy)hexanoic acidIdentification of a Plasma Membrane-associated Guanine Nucleotide Exchange Factor for ARF6 in Chromaffin CellsRegulated Exocytosis in Chromaffin CellsSynthetic CCK8 analogs with antagonist activity on pancreatic receptors: in vivo study in the rat, compared to non-peptidic antagonists[Structure-activity relationship of cystokinins: analogs exhibiting selective activity]Receptor-induced heterologous desensitization of receptor-regulated phospholipase CCyclic AMP-induced desensitization of G-protein-regulated phospholipase C in turkey erythrocyte membranes
P50
Q28583038-605BCF53-D366-48A2-915B-1AA18197639EQ33726405-5B49744F-5F08-4D19-9A7D-0175FCD414E3Q33742140-4C4BE2D3-44A1-4B54-9760-CA0040FAD1DDQ34040349-5097F6D5-8210-469B-9FF9-E2C0D6F54783Q35080258-2BC36E20-EF21-4978-988A-00F72F510A81Q35172268-6A47943C-315E-44A0-9C6A-A2CFF0827405Q35196319-E6779BB0-02FD-4A74-BD56-F401D917159BQ36092947-1D390136-C57E-45A1-9CD5-E526B792B1F2Q37239971-3948EC83-0E3D-4F85-8F6D-E6B4FCC2E4ACQ37936556-C3D92C18-EE7E-482C-9D14-5F5CA171B018Q38301456-9D35413F-8E84-4692-B179-3B191AA9CA05Q39290100-921A8A3A-FCB8-4246-A9B0-B1EF8E8D47A5Q40138602-E14A9544-B535-4582-9474-F07EDFA4B12CQ40280535-78E499D1-42BE-490F-A91D-DAE5DCAEC7BDQ41082653-26480A6E-7A1C-437C-A147-A115947BDD13Q42460373-A688C994-BF4A-4748-917B-44E893CFC1DEQ44149302-D14A77A9-96D1-45A4-AD7F-04A4C989BA59Q44186014-A80CD8CE-23E4-43FD-8AEF-25430F86E928Q44495506-C8BC6E57-B5FB-4EC8-A1C7-D780CEA700C2Q44710406-A5BA7D1F-A9C1-4B57-89DD-208CDEFFB811Q45056705-B7096073-361D-41F9-9211-41066F753073Q45223354-D3235A44-DA67-429A-BBAD-092E7CC5D4A1Q45297417-6566C890-7753-4AFB-82B7-8F3BD14D4355Q47145684-70976C1D-728A-48A3-B2E4-6E49D5904045Q48112220-EA25A5F2-52F5-4450-8086-0A66DC52E79CQ48170710-46CFE104-4686-4E06-B39D-11D89F5A8E32Q48358524-630AE64D-3D8A-40ED-8B0A-4F35CA1BC9DFQ48395258-6A21347D-CF07-415D-9F71-56DD7C4B5E69Q48407956-C98AA3BC-DF95-4D95-872D-1A6EE0ED80CAQ51008941-04E4CDFB-DD49-42B9-A43D-7E04905746D2Q52609742-195CA43F-01C4-4C82-9D24-7CF9DE7E62BEQ53419341-B182B98C-3065-4081-8BAB-E54097C80E75Q57753436-AB94F456-E823-4C04-BC8E-DAF7A17DB545Q58105140-07C7D151-C167-45D4-BC06-5C28A988C981Q58423748-CD87ACBC-394C-41EA-B9B3-939FCAFB9D39Q58423756-2966EF6F-6AAD-4D33-B8C6-E4C79629CF73Q67695964-2C4ECB3E-5411-4455-8A26-F92DB42AEF8BQ70190767-594C630E-ED4A-411F-92FC-10E42B3AC5EDQ70911474-DAFFF546-189F-474F-9733-8100CFA39FA6Q71865684-8C05C450-D9C2-4B33-B5B6-97E4263701B6
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Marie-Christine Galas
@ast
Marie-Christine Galas
@de
Marie-Christine Galas
@en
Marie-Christine Galas
@es
Marie-Christine Galas
@fr
Marie-Christine Galas
@nl
Marie-Christine Galas
@pt
Marie-Christine Galas
@sv
type
label
Marie-Christine Galas
@ast
Marie-Christine Galas
@de
Marie-Christine Galas
@en
Marie-Christine Galas
@es
Marie-Christine Galas
@fr
Marie-Christine Galas
@nl
Marie-Christine Galas
@pt
Marie-Christine Galas
@sv
prefLabel
Marie-Christine Galas
@ast
Marie-Christine Galas
@de
Marie-Christine Galas
@en
Marie-Christine Galas
@es
Marie-Christine Galas
@fr
Marie-Christine Galas
@nl
Marie-Christine Galas
@pt
Marie-Christine Galas
@sv
P214
P269
P106
P21
P214
P269
P31
P496
0000-0002-3766-7103
P7859
viaf-210221746